Harnessing the Power of Bispecific ADCs, Novel & Dual Payload Conjugates to Develop Next-Generation ADCs

  • Highlighting design and preclinical development of IBI3005 bispecific ADC targeting EGFR & HER3
  • Assessing rationale and performance of ADCs with dual targeting and dual payload design versus classical design
  • Leveraging novel TOP1i payloads in bispecific and dual-payload ADCs